{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T14:10:44Z","timestamp":1775571044916,"version":"3.50.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Kratom is a psychoactive botanical that is increasingly popular in the United States. While potential risks of kratom use have been identified, research on harm reduction strategies and contextual factors contributing to adverse reactions is limited. Given that kratom is federally unregulated at present, and a variety of kratom products are widely available on the commercial market, more data are needed to inform harm reduction efforts and public health messaging.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>102 participants (mean age\u2009=\u200922.34 years, 39.2% women) were recruited from ethnobotanical tea bars in Northern Colorado to complete a survey on kratom use, which included questions pertaining to adverse experiences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Most participants (75.5%) reported experiencing an adverse reaction to kratom at least once in the past, with a wide range of kratom doses reportedly consumed during these experiences. Adverse reactions were most commonly reported to occur in the context of consuming kratom on an empty stomach, consuming alongside certain foods, lack of hydration, and combining kratom with other substances. Participants employed a variety of strategies in attempt to mitigate adverse reactions, such as stopping or pacing their use of kratom and other substances, modulating hydration and food intake, and engaging in rest and recovery behaviors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Adverse reactions to kratom may be associated with certain contextual factors. Several techniques are reportedly used to mitigate adverse reactions, but the efficacy of these techniques is unknown. More data are needed to understand the causes and consequences of adverse reactions to kratom, and to better understand potential harm reduction strategies for reducing adverse experiences. More research could also shed light on the extent to which kratom serving size and various product formulations (e.g. whole leaf vs. extracts) are predictive of adverse effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12954-025-01382-x","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T07:25:19Z","timestamp":1772436319000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Characteristics of adverse reactions to kratom and implementation of harm reduction strategies in a sample of ethnobotanical tea bar patrons in Colorado"],"prefix":"10.1186","volume":"23","author":[{"given":"Cianna J.","family":"Piercey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riley","family":"Ahern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabella","family":"Packwood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carter","family":"Bruning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devin","family":"Henry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesse","family":"Ruehrmund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katelyn","family":"Weldon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsten E.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hollis C.","family":"Karoly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"key":"1382_CR1","doi-asserted-by":"publisher","unstructured":"Kamble SH, Berthold EC, Kanumuri SRR, King TI, Kuntz MA, Le\u00f3n F, et al. Metabolism of Speciociliatine, an overlooked Kratom alkaloid for its potential Pharmacological effects. AAPS J. 2022;24. https:\/\/doi.org\/10.1208\/s12248-022-00736-8.","DOI":"10.1208\/s12248-022-00736-8"},{"key":"1382_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.751656","author":"NA Hanapi","year":"2021","unstructured":"Hanapi NA, Chear NJY, Azizi J, Yusof SR. Kratom alkaloids: interactions with Enzymes, Receptors, and cellular barriers. Front Pharmacol. 2021. https:\/\/doi.org\/10.3389\/fphar.2021.751656.","journal-title":"Front Pharmacol"},{"key":"1382_CR3","doi-asserted-by":"publisher","unstructured":"Obeng S, Leon F, Patel A, Zuarth Gonzalez JD, da Silva LC, Restrepo LF, et al. Interactive effects of m-Opioid and Adrenergic-a2 receptor agonists in rats: Pharmacological investigation of the primary Kratom alkaloid Mitragynine and its metabolite 7-Hydroxymitragynine. J Pharmacol Exp Ther. 2022;383. https:\/\/doi.org\/10.1124\/jpet.122.001192.","DOI":"10.1124\/jpet.122.001192"},{"key":"1382_CR4","doi-asserted-by":"publisher","unstructured":"Obeng S, Kamble SH, Reeves ME, Restrepo LF, Patel A, Behnke M, et al. Investigation of the adrenergic and opioid binding Affinities, metabolic Stability, plasma protein binding Properties, and functional effects of selected Indole-Based Kratom alkaloids. J Med Chem. 2020;63. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b01465.","DOI":"10.1021\/acs.jmedchem.9b01465"},{"key":"1382_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s40429-023-00472-9","author":"S Mukhopadhyay","year":"2023","unstructured":"Mukhopadhyay S, Gupta S, Wilkerson JL, Sharma A, McMahon LR, McCurdy CR. Receptor selectivity and therapeutic potential of Kratom in substance use disorders. Curr Addict Rep. 2023. https:\/\/doi.org\/10.1007\/s40429-023-00472-9.","journal-title":"Curr Addict Rep"},{"key":"1382_CR6","doi-asserted-by":"publisher","unstructured":"Chen Y, McCurdy C, Mottinelli M, Canal C. Probing the activity of Mitragyna speciosa (Kratom) alkaloids at serotonin G Protein-Coupled receptors. FASEB J. 2022;36. https:\/\/doi.org\/10.1096\/fasebj.2022.36.s1.r2407.","DOI":"10.1096\/fasebj.2022.36.s1.r2407"},{"key":"1382_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.disamonth.2022.101442","author":"O Grundmann","year":"2023","unstructured":"Grundmann O, Hendrickson RG, Greenberg MI. Kratom: History, pharmacology, current user trends, adverse health effects and potential benefits. Dis Mon. 2023. https:\/\/doi.org\/10.1016\/j.disamonth.2022.101442. 69.","journal-title":"Dis Mon"},{"key":"1382_CR8","unstructured":"American Kratom Association. Natural Kratom Products vs. Adulterated Kratom Products\u2014Where the FDA Went Wrong [Internet]. 2019 [cited 2024 Nov 17]. https:\/\/www.csakratom.org\/uploads\/AKA_Natural_vs_Adulterated_Kratom_Products_4c67264169.pdf?updated_at=2022-11-01T20:22:09.340Z. Accessed 17 Nov 2024."},{"key":"1382_CR9","doi-asserted-by":"publisher","DOI":"10.1080\/00952990.2022.2041026","author":"O Grundmann","year":"2022","unstructured":"Grundmann O, Veltri CA, Morcos D, Knightes D, Smith KE, Singh D, et al. Exploring the self-reported motivations of Kratom (Mitragyna speciosa Korth.) use: a cross-sectional investigation. Am J Drug Alcohol Abuse. 2022. https:\/\/doi.org\/10.1080\/00952990.2022.2041026.","journal-title":"Am J Drug Alcohol Abuse"},{"key":"1382_CR10","doi-asserted-by":"publisher","unstructured":"Smith KE, Lawson T. Prevalence and motivations for Kratom use in a sample of substance users enrolled in a residential treatment program. Drug Alcohol Depend. 2017;180. https:\/\/doi.org\/10.1016\/j.drugalcdep.2017.08.034.","DOI":"10.1016\/j.drugalcdep.2017.08.034"},{"key":"1382_CR11","doi-asserted-by":"publisher","first-page":"E2353401","DOI":"10.1001\/jamanetworkopen.2023.53401","volume":"7","author":"KE Smith","year":"2024","unstructured":"Smith KE, Panlilio LV, Feldman JD, Grundmann O, Dunn KE, McCurdy CR, et al. Ecological momentary assessment of Self-Reported Kratom Use, Effects, and motivations among US adults. JAMA Netw Open Am Med Association. 2024;7:E2353401. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.53401.","journal-title":"JAMA Netw Open Am Med Association"},{"key":"1382_CR12","doi-asserted-by":"publisher","unstructured":"Smith KE, Feldman JD, Dunn KE, McCurdy CR, Weiss ST, Grundmann O, et al. Examining the Paradoxical effects of kratom: a narrative inquiry. Front Pharmacol. 2023;14. https:\/\/doi.org\/10.3389\/fphar.2023.1174139.","DOI":"10.3389\/fphar.2023.1174139"},{"key":"1382_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s40429-023-00466-7","author":"JD Feldman","year":"2023","unstructured":"Feldman JD, Schriefer D, Smith KE, Weiss ST, Butera G, Dunn KE, et al. Omissions, Ambiguities, and underuse of causal assessment tools: a systematic review of case reports on patients who use Kratom. Curr Addict Rep. 2023. https:\/\/doi.org\/10.1007\/s40429-023-00466-7.","journal-title":"Curr Addict Rep"},{"key":"1382_CR14","doi-asserted-by":"publisher","unstructured":"Alsarraf E, Myers J, Culbreth S, Fanikos J. Kratom from head to Toe\u2014Case reviews of adverse events and toxicities. Curr Emerg Hosp Med Rep. 2019;7. https:\/\/doi.org\/10.1007\/s40138-019-00194-1.","DOI":"10.1007\/s40138-019-00194-1"},{"key":"1382_CR15","doi-asserted-by":"publisher","unstructured":"Hill K, Grundmann O, Smith KE, Stanciu CN. Prevalence of Kratom use disorder among Kratom consumers. J Addict Med. 2024;18. https:\/\/doi.org\/10.1097\/ADM.0000000000001290.","DOI":"10.1097\/ADM.0000000000001290"},{"key":"1382_CR16","doi-asserted-by":"publisher","unstructured":"Rogers JM, Colvin K, Epstein DH, Grundmann O, McCurdy CR, Smith KE. Growing pains with kratom: experiences discussed in subreddits contrast with satisfaction expressed in surveys. Front Pharmacol [Internet]. 2024;15. https:\/\/www.frontiersin.org\/journals\/pharmacology\/articles\/https:\/\/doi.org\/10.3389\/fphar.2024.1412397","DOI":"10.3389\/fphar.2024.1412397"},{"key":"1382_CR17","doi-asserted-by":"publisher","unstructured":"Smith KE, Epstein DH, Weiss ST. Controversies in Assessment, Diagnosis, and Treatment of Kratom Use Disorder. Curr Psychiatry Rep. Springer; 2024. pp. 487\u201396. https:\/\/doi.org\/10.1007\/s11920-024-01524-1","DOI":"10.1007\/s11920-024-01524-1"},{"key":"1382_CR18","doi-asserted-by":"crossref","unstructured":"Swart BB, Reznikoff C, Steen K. Isolated Kratom use disorder treated with Extended-Release buprenorphine taper. J Addict Med [Internet]. 2024;18(5):602\u2013\u2013604. https:\/\/journals.lww.com\/journaladdictionmedicine\/fulltext\/2024\/09000\/isolated_kratom_use_disorder_treated_with.23.aspx","DOI":"10.1097\/ADM.0000000000001328"},{"key":"1382_CR19","doi-asserted-by":"publisher","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th Edition. Diagnostic and Statistical Manual of Mental Disorders, 5th Edition. 2013. https:\/\/doi.org\/10.1176\/appi.books.9780890425596.893619","DOI":"10.1176\/appi.books.9780890425596.893619"},{"key":"1382_CR20","doi-asserted-by":"publisher","unstructured":"Corkery JM, Streete P, Claridge H, Goodair C, Papanti D, Orsolini L, et al. Characteristics of deaths associated with Kratom use. J Psychopharmacol. 2019;33. https:\/\/doi.org\/10.1177\/0269881119862530.","DOI":"10.1177\/0269881119862530"},{"key":"1382_CR21","doi-asserted-by":"publisher","unstructured":"Post S, Spiller HA, Chounthirath T, Smith GA. Kratom exposures reported to united States poison control centers: 2011\u20132017. Clin Toxicol. 2019;57. https:\/\/doi.org\/10.1080\/15563650.2019.1569236.","DOI":"10.1080\/15563650.2019.1569236"},{"key":"1382_CR22","doi-asserted-by":"publisher","unstructured":"Smith KE, Rogers JM, Dunn KE, Grundmann O, McCurdy CR, Schriefer D, et al. Searching for a signal: Self-Reported Kratom Dose-Effect relationships among a sample of US adults with regular Kratom use histories. Front Pharmacol. 2022;13. https:\/\/doi.org\/10.3389\/fphar.2022.765917.","DOI":"10.3389\/fphar.2022.765917"},{"key":"1382_CR23","doi-asserted-by":"publisher","unstructured":"Martens MP, Ferrier AG, Sheehy MJ, Corbett K, Anderson DA, Simmons A. Development of the protective behavioral strategies survey. J Stud Alcohol. 2005;66. https:\/\/doi.org\/10.15288\/jsa.2005.66.698.","DOI":"10.15288\/jsa.2005.66.698"},{"key":"1382_CR24","doi-asserted-by":"publisher","unstructured":"Prince MA, Jenzer T, Brown W, Hetelekides EM, Mumm RA, Collins RL. Examining cannabis protective behavioral strategy use using multiple methods. Drugs Alcohol Today. 2019;19. https:\/\/doi.org\/10.1108\/DAT-10-2018-0061.","DOI":"10.1108\/DAT-10-2018-0061"},{"key":"1382_CR25","doi-asserted-by":"publisher","unstructured":"Piercey CJ, Gray B, Sung A, Henry D, Karoly HC. Protective behavioral strategies for psychedelic use: A mini review of the Evidence. psychedelic medicine. Mary Ann Liebert Inc; 2024. https:\/\/doi.org\/10.1089\/psymed.2023.0052.","DOI":"10.1089\/psymed.2023.0052"},{"key":"1382_CR26","doi-asserted-by":"publisher","unstructured":"Pedersen ER, Huang W, Dvorak RD, Prince MA, Hummer JF, Anthenien AM, et al. The protective behavioral strategies for marijuana scale: further examination using item response theory. Psychol Addict Behav. 2017;31. https:\/\/doi.org\/10.1037\/adb0000271.","DOI":"10.1037\/adb0000271"},{"key":"1382_CR27","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1037\/pha0000498","volume":"29","author":"R Peterson","year":"2021","unstructured":"Peterson R, Kramer MP, Pinto D, De Leon AN, Leary AV, Marin AA, et al. A comprehensive review of measures of protective behavioral strategies across various risk factors and associated PBS-related interventions. Exp Clin Psychopharmacol Am Psychol Association. 2021;29:236\u201350. https:\/\/doi.org\/10.1037\/pha0000498.","journal-title":"Exp Clin Psychopharmacol Am Psychol Association"},{"key":"1382_CR28","doi-asserted-by":"publisher","unstructured":"Fern\u00e1ndez-Calder\u00f3n F, D\u00edaz-Batanero C, Barratt MJ, Palamar JJ. Harm reduction strategies related to dosing and their relation to harms among festival attendees who use multiple drugs. Drug Alcohol Rev. 2019;38. https:\/\/doi.org\/10.1111\/dar.12868.","DOI":"10.1111\/dar.12868"},{"key":"1382_CR29","doi-asserted-by":"publisher","unstructured":"Vidal Gin\u00e9 C, Fern\u00e1ndez Calder\u00f3n F, L\u00f3pez Guerrero J. Patterns of use, harm reduction strategies, and their relation to risk behavior and harm in recreational ketamine users. Am J Drug Alcohol Abuse. 2016;42. https:\/\/doi.org\/10.3109\/00952990.2016.1141211.","DOI":"10.3109\/00952990.2016.1141211"},{"key":"1382_CR30","doi-asserted-by":"publisher","unstructured":"Edwards D, Csontos J, Pascoe MJ, Westwell A, Gillen E, Bennett C et al. A rapid scoping review of harm reduction strategies for ecstasy (MDMA) users in recreational settings. 2022; https:\/\/doi.org\/10.21203\/rs.3.rs-2178425\/v1","DOI":"10.21203\/rs.3.rs-2178425\/v1"},{"key":"1382_CR31","doi-asserted-by":"publisher","first-page":"104456","DOI":"10.1016\/j.drugpo.2024.104456","volume":"128","author":"O Erinoso","year":"2024","unstructured":"Erinoso O, Daugherty R, Kirk MR, Harding RW, Etchart H, Reyes A, et al. Safety strategies and harm reduction for methamphetamine users in the era of Fentanyl contamination: a qualitative analysis. Int J Drug Policy Elsevier. 2024;128:104456.","journal-title":"Int J Drug Policy Elsevier"},{"key":"1382_CR32","doi-asserted-by":"publisher","unstructured":"Palamar JJ, Barratt MJ. Prevalence of reagent test-kit use and perceptions of purity among ecstasy users in an electronic dance music scene in new York City. Drug Alcohol Rev. 2019;38. https:\/\/doi.org\/10.1111\/dar.12882.","DOI":"10.1111\/dar.12882"},{"key":"1382_CR33","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12954-025-01252-6","volume":"22","author":"CJ Piercey","year":"2025","unstructured":"Piercey CJ, Pince CL, Karoly HC. Highlighting variability in Fentanyl test strip instructions using thematic content analysis. Harm Reduct J Springer. 2025;22:110.","journal-title":"Harm Reduct J Springer"},{"key":"1382_CR34","doi-asserted-by":"crossref","unstructured":"Hurlocker MC, Pearson MR. Opioid protective behavioral strategies scale (OPBSS): development and psychometric evaluation. Exp clin psychopharmacol. American Psychological Association; 2024.","DOI":"10.1037\/pha0000738"},{"key":"1382_CR35","doi-asserted-by":"publisher","unstructured":"De Leon AN, Dvorak RD, Smallman R, Arthur K, Piercey C. Using counterfactual thinking theory to change alcohol protective behavioural strategy use intentions. Br J Health Psychol. 2022;27. https:\/\/doi.org\/10.1111\/bjhp.12535.","DOI":"10.1111\/bjhp.12535"},{"key":"1382_CR36","doi-asserted-by":"publisher","unstructured":"Mian MN, Altman BR, Low F, Earleywine M. Development of the Protective Strategies for Psychedelics Scale: A novel inventory to assess safety strategies in the context of psychedelics. Journal of Psychopharmacology. SAGE Publications Ltd; 2023; https:\/\/doi.org\/10.1177\/02698811231214060","DOI":"10.1177\/02698811231214060"},{"key":"1382_CR37","doi-asserted-by":"publisher","DOI":"10.1177\/11782218221095873","author":"CW Striley","year":"2022","unstructured":"Striley CW, Hoeflich CC, Viegas AT, Berkowitz LA, Matthews EG, Akin LP, et al. Health effects associated with Kratom (Mitragyna speciosa) and polysubstance use: A narrative review. Subst Abuse. 2022. https:\/\/doi.org\/10.1177\/11782218221095873.","journal-title":"Subst Abuse"},{"key":"1382_CR38","doi-asserted-by":"publisher","first-page":"100361","DOI":"10.1016\/j.dadr.2025.100361","volume":"16","author":"CJ Piercey","year":"2025","unstructured":"Piercey CJ, Bunch J, Cameron J, Ahern R, Packwood I, Bruning C, et al. Kratom use among ethnobotanical tea bar patrons in colorado: subjective drug effects, adverse reactions, and perceived benefits of use. Drug Alcohol Depend Rep [Internet]. 2025;16:100361. https:\/\/doi.org\/10.1016\/j.dadr.2025.100361.","journal-title":"Drug Alcohol Depend Rep [Internet]"},{"key":"1382_CR39","doi-asserted-by":"publisher","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3. https:\/\/doi.org\/10.1191\/1478088706qp063oa.","DOI":"10.1191\/1478088706qp063oa"},{"key":"1382_CR40","doi-asserted-by":"publisher","unstructured":"Coe MA, Pillitteri JL, Sembower MA, Gerlach KK, Henningfield JE. Kratom as a substitute for opioids: results from an online survey. Drug Alcohol Depend. 2019;202. https:\/\/doi.org\/10.1016\/j.drugalcdep.2019.05.005.","DOI":"10.1016\/j.drugalcdep.2019.05.005"},{"key":"1382_CR41","doi-asserted-by":"publisher","unstructured":"Grundmann O. Patterns of Kratom use and health impact in the US\u2014Results from an online survey. Drug Alcohol Depend. 2017;176. https:\/\/doi.org\/10.1016\/j.drugalcdep.2017.03.007.","DOI":"10.1016\/j.drugalcdep.2017.03.007"},{"key":"1382_CR42","doi-asserted-by":"publisher","unstructured":"Garcia-Romeu A, Cox DJ, Smith KE, Dunn KE, Griffiths RR. Kratom (Mitragyna speciosa): user demographics, use patterns, and implications for the opioid epidemic. Drug Alcohol Depend. 2020;208. https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.107849.","DOI":"10.1016\/j.drugalcdep.2020.107849"},{"key":"1382_CR43","doi-asserted-by":"publisher","unstructured":"Rogers JM, Smith KE, Strickland JC, Epstein DH. Kratom use in the US: both a regional phenomenon and a white Middle-Class phenomenon? Evidence from NSDUH 2019 and an online convenience sample. Front Pharmacol. 2021;12. https:\/\/doi.org\/10.3389\/fphar.2021.789075.","DOI":"10.3389\/fphar.2021.789075"},{"key":"1382_CR44","doi-asserted-by":"publisher","DOI":"10.1080\/10550887.2020.1788914","author":"JR Covvey","year":"2020","unstructured":"Covvey JR, Vogel SM, Peckham AM, Evoy KE. Prevalence and characteristics of self-reported Kratom use in a representative US general population sample. J Addict Dis. 2020. https:\/\/doi.org\/10.1080\/10550887.2020.1788914.","journal-title":"J Addict Dis"},{"key":"1382_CR45","doi-asserted-by":"crossref","unstructured":"Vadiei N, Evoy KE, Grundmann O. The impact of diverse Kratom products on use Patterns, Dependence, and toxicity. Curr Psychiatry Rep. Springer;; 2025. pp. 1\u20139.","DOI":"10.1007\/s11920-025-01631-7"},{"key":"1382_CR46","doi-asserted-by":"publisher","unstructured":"Swogger MT, Hart E, Erowid F, Erowid E, Trabold N, Yee K, et al. Experiences of Kratom users: A qualitative analysis. J Psychoact Drugs. 2015;47. https:\/\/doi.org\/10.1080\/02791072.2015.1096434.","DOI":"10.1080\/02791072.2015.1096434"},{"key":"1382_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainresbull.2016.05.004","author":"D Singh","year":"2016","unstructured":"Singh D, Narayanan S, Vicknasingam B. Traditional and non-traditional uses of Mitragynine (Kratom): A survey of the literature. Brain Res Bull. 2016. https:\/\/doi.org\/10.1016\/j.brainresbull.2016.05.004.","journal-title":"Brain Res Bull"},{"key":"1382_CR48","doi-asserted-by":"publisher","unstructured":"Singh D, Narayanan S, Grundmann O, Dzulkapli E, Bin VB. Effects of Kratom (Mitragyna speciosa Korth.) use in regular users. Subst Use Misuse. 2019;54. https:\/\/doi.org\/10.1080\/10826084.2019.1645178.","DOI":"10.1080\/10826084.2019.1645178"},{"key":"1382_CR49","doi-asserted-by":"publisher","unstructured":"Smith KE, Rogers JM, Schriefer D, Grundmann O. Therapeutic benefit with caveats? Analyzing social media data to understand the complexities of Kratom use. Drug Alcohol Depend. 2021;226. https:\/\/doi.org\/10.1016\/j.drugalcdep.2021.108879.","DOI":"10.1016\/j.drugalcdep.2021.108879"},{"key":"1382_CR50","doi-asserted-by":"publisher","unstructured":"Kerrigan S, Basiliere S, Kratom. A systematic review of toxicological issues. WIREs Forensic Sci. 2022;4. https:\/\/doi.org\/10.1002\/wfs2.1420.","DOI":"10.1002\/wfs2.1420"},{"key":"1382_CR51","doi-asserted-by":"publisher","unstructured":"Grundmann O, Garcia-Romeu A, McCurdy CR, Sharma A, Smith KE, Swogger MT, et al. Not all Kratom is equal: the important distinction between native leaf and extract products. Addiction. 2024;119. https:\/\/doi.org\/10.1111\/add.16366.","DOI":"10.1111\/add.16366"},{"key":"1382_CR52","doi-asserted-by":"publisher","unstructured":"Smith KE, Boyer EW, Grundmann O, McCurdy CR, Sharma A. The rise of novel, semi-synthetic 7-hydroxymitragnine products. Addiction. John Wiley and Sons Inc; 2024. https:\/\/doi.org\/10.1111\/add.16728","DOI":"10.1111\/add.16728"},{"key":"1382_CR53","doi-asserted-by":"publisher","unstructured":"Hill K, Gibson S, Grundmann O, Smith KE, Ballard J, Stanciu CN. Evaluating health information provided to Kratom consumers by good manufacturing practice-qualified vendors. Subst Abuse Treat Prev Policy BioMed Cent Ltd. 2023;18. https:\/\/doi.org\/10.1186\/s13011-023-00531-4.","DOI":"10.1186\/s13011-023-00531-4"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-025-01382-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-025-01382-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-025-01382-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T13:23:37Z","timestamp":1775568217000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12954-025-01382-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1382"],"URL":"https:\/\/doi.org\/10.1186\/s12954-025-01382-x","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"assertion":[{"value":"20 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Review Board at Colorado State University. All individuals enrolled in the study consented to participate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Within the past three years, KES has served as a paid scientific advisor to the International Plant and Herbal Alliance and the Kratom Coalition and serves as an expert witness in legal cases involving kratom.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"70"}}